YRK York Pharma

    RNS Number : 1680K
  York Pharma plc
  16 December 2008
   

    York Pharma plc

    ("York Pharma" or the "Company")

    York Pharma plc receives a Translation Award of �100,014 from the Wellcome Trust for the development of a specialist wound care product



    London, UK, 16 December 2008 York Pharma plc, the AIM-listed (AIM: YRK) strategic acquirer, developer and marketer of pharmaceutical
products in the field of dermatology, today announces that it has received programme-related funding of �100,014 from the Wellcome Trust as
a Translation Award for the development of a cell-free dressing to accelerate re-epithelialisation in partial thickness burns wounds.

    In consideration of this funding, the Company can confirm that 526,389 York Pharma 5p ordinary shares (the "Placing Shares") have been
conditionally placed with the Wellcome Trust at a price of 19 pence per share. Application has been made to the London Stock Exchange plc
for the Placing Shares to be admitted to trading on AIM. It is expected that the Placing Shares will be admitted to trading on AIM and that
dealings in such shares will commence on 19 December 2008.

    Key Points

    *     Following the acquisition of Flammazine*, Flammacerium*, Myskin* and Cryoskin*, York Pharma plc has taken a strong strategic
position in the woundcare market;

    *     The Wellcome Trust provides Translation Awards for the development of novel, innovative healthcare products and medicines;

    *     The Translation Award granted to York Pharma plc by the Wellcome Trust will assist York in developing a cell-free dressing to
accelerate re-epithelialisation in partial thickness burns wounds. The approach aims to accelerate keratinocyte migration and reduce the
ability of keratinocytes to contract the wound bed. York will combine this approach with in house plasma polymer technology to promote
guidance of the cells to the wound area.  

    *     With the acquisition of the assets of CellTran*, York Pharma now owns a MHRA accredited GMP production facility for Myskin* and
Cryoskin* and is able to produce GMP material for the woundcare market. The novel dressing will complement the current product portfolio and
form part of the normal treatment regimen for burns patients.

    Ted Bianco, Director of Technology Transfer at the Wellcome Trust, said:
    "Development of specialist healthcare products is often an overlooked area commercially due to the predominant 'blockbuster' mentality.
We are very pleased to apply translational funding toward specialist healthcare needs especially when the intervention being developed
originates from a strong scientific concept."  

    Terry Sadler, Chief Executive of York Pharma, commented:
    "We are delighted with the award from the Wellcome Trust which affords us the opportunity to develop a much needed product in the
treatment of burns that compliments our four current products in our woundcare portfolio. The Wellcome Trust is respected world-wide for
supporting the very highest quality research and its support endorses our commitment to develop novel, innovative products with a sound
scientific basis." 

    --END--

    For further information please contact:

 York Pharma plc                           Tel: +44 (0)870 067 2563 
 Terry Sadler, Chief Executive Officer
 Finn Cap                                 Tel: +44 (0)207 600 1658 
 Stephen Norcross
 Collins Stewart Europe Limited           Tel: +44 (0)207 523 8000 
 Hugh Field/Adam Cowen
 Financial Dynamics                       Tel: +44 (0)207 831 3113 
 David Yates/Ben Brewerton/Emma Thompson


    About the Wellcome Trust
    The Wellcome Trust is the largest charity in the UK. It funds innovative biomedical research, in the UK and internationally, spending
over �600 million each year to support the brightest scientists with the best ideas. The Wellcome Trust supports public debate about
biomedical research and its impact on health and wellbeing. http://www.wellcome.ac.uk

    About the woundcare market
    The global wound care market is huge. Estimates range for US$ 7 billion to US$ 13 billion, depending on source and exact market
definition. The majority of the market is made up of 'traditional' wound care such as gauzes, bandages and other dressings. Advanced wound
care therapies (which include CellTran's products) make up a significant proportion of the market. More significantly, the advanced market
is growing rapidly as there is a gradual transition from traditional to advanced treatments. Frost and Sullivan valued the global advanced
wound care market at US$ 1.6 billion in 2005, with an 11% annual growth rate. 

    Current therapies for the treatment of chronic wounds are largely unsatisfactory, both from a clinical and economic point of view.
Approximately 40% of chronic wounds fail to heal, even with current standard therapies. Furthermore, the overall annual treatment costs for
wounds such as chronic ulcers are considerable, ranging from �7,000 to �20,000 per case, depending on the severity of the wound. This is of
serious concern to governments that seek to limit health care expenditures.

    About York Pharma plc
    York Pharma is an AIM-listed strategic acquirer, developer and marketer of pharmaceutical products in the field of dermatology. Its
portfolio now embraces skin diseases that make up approximately 87% of the global $10.6bn dermatology market.  For further information,
please go to www.yorkpharma.com.

This information is provided by RNS
The company news service from the London Stock Exchange
 
  END 
 
MSCQELFFVLBFFBQ

York Pharma (LSE:YRK)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024

York Pharma (LSE:YRK)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024